T1	Participants 40 153	postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer
T2	Participants 155 215	International Breast Cancer Study Group Trials VII and 12-93
T3	Participants 719 854	cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status
